Angiotensin II (Ang II) is a medication that is used to treat hypotension resulting from septic shock or other distributive shock. It is a synthetic vasoconstrictor peptide that is identical to human hormone angiotensin II  and is marketed under the brand name Giapreza. The Food and Drug Administration approved the use of angiotensin II in December 2017 to treat low blood pressure resulting from septic shock.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses
Angiotensin II is a vasoconstrictor used to increase blood pressure in adults with septic or other distributive shock. Angiotensin II is a naturally occurring hormone secreted as part of the renin-angiotensin system that results in powerful systemic vasoconstriction. The vasopressor effects of angiotensin have been studied since it was first isolated in the late 1930s. Vasopressors are defined as agents that combat vasodilatory shock by inducing peripheral vasoconstriction. Commonly used vasopressors include catecholamine (e.g., dopamine, norepinephrine, epinephrine) and non-catecholamine (e.g., vasopressin). but these agents are not always effective in reversing vasodilatory shock, and their use can be associated with significant side effects including limb ischemia and cardiac arrhythmia. Angiotensin II is as a treatment option that can increase blood pressure and allow catecholamine dose reductions. Angiotensin II must be administered as an intravenous infusion diluted in 0.9% sodium chloride prior to use. The recommended starting dosage of angiotensin II is 20 nanograms (ng)/kg/min via continuous intravenous infusion. Administration through a central venous line is recommended.
Urinary preparations
Purified urinary FSH (75 IU FSH and ≤ 2 IU of LH)Generic
urofollitropin for injection, purified.Brands
Bravelle, U.S., (≤ 2 IU LH)
Metrodin, U.S. and Canada, (≤ 1 IU LH)
Fertinorm Hp, (Canada)Highly purified urinary FSH (75 IU FSH and ≤ 0.1 IU LH/1000 IU FSH)Generic
urofollitropin for injection, (highly) purified.Dosage
typically 75 - 300, but as high as 600 IU / dayBrands
Fertinex (≤ 0.1 IU LH/1000 IU FSH)

Recombinant preparations
Follitropin alfaGeneric
Follitropin alfa injectionBrandsGonal-f
Cinnal-f
Fertilex
Ovaleap
BemfolaFollitropin betaGeneric
follitropin beta injectionBrands
Follistim AQ
PuregonFollitropin deltaGeneric
follitropin delta injectionBrands
RekovelleThe package insert for Gonal-f states that based on physio-chemical tests and bioassays that follitropin beta and follitropin alfa are indistinguishable. Two studies showed no difference. However, a more recent study showed there may be a slight clinical difference, with the alfa form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels.The package insert for Puregon states that structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (hFSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural hFSH. However, these small differences do not affect the bioactivity compared to natural hFSH. Gonal-f was approved for medical use in the European Union in October 1995.Puregon was approved for medical use in the European Union in February 1996.Rekovelle was approved for medical use in the European Union in December 2016. Biosimilars
Ovaleap was approved for medical use in the European Union in September 2013.